Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

doi:10.1359/jbmr.081112

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research - 1 Feb 2009

Kostenuik Paul J, Nguyen Hung Q, McCabe James, Warmington Kelly S, Kurahara Carol, Sun Ning, Chen Ching, Li Luke, Cattley Russ C, Van Gwyneth, Scully Shelia, Elliott Robin, Grisanti Mario, Morony Sean, Tan Hong Lin, Asuncion Frank, Li Xiaodong, Ominsky Michael S, Stolina Marina, Dwyer Denise, Dougall William C, Hawkins Nessa, Boyle William J, Simonet William S, Sullivan John K

Abstract excerpt

RANKL is a TNF family member that mediates osteoclast formation, activation, and survival by activating RANK. The proresorptive effects of RANKL are prevented by binding to its soluble inhibitor osteoprotegerin (OPG). Recombinant human OPG-Fc recognizes RANKL from multiple species and reduced bone resorption and increased bone volume, density, and strength in a number of rodent models of bone disease. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibody Affinity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Resorption

Share to Gene Knock-In Techniques

Share to Hypercalcemia

Share to Osteoclasts

Share to Osteoprotegerin

Share to RANK Ligand

Share to X-Ray Microtomography

Source

Open in PubMed

Identifiers

PMID: 19016581
DOI: 10.1359/jbmr.081112

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.PMID 19016581Read ↗

Novel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic MiceSemantic proximity Read ↗

Biology of the RANKLâ€“RANKâ€“OPG System in Immunity, Bone, and BeyondSemantic proximity Read ↗

Denosumab: mechanism of action and clinical outcomesSemantic proximity Read ↗

Role of RANKL Signaling in Bone HomeostasisSemantic proximity Read ↗

Historically significant events in the discovery of RANK/RANKL/OPGSemantic proximity Read ↗

RANKL cytokine: from pioneer of the osteoimmunology era to cure for a rare disease.Semantic proximity Read ↗

Disabling of Receptor Activator of Nuclear Factor-κB (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in VivoSemantic proximity Read ↗

RANKL and RANK in Cancer TherapySemantic proximity Read ↗

RANK-L and RANK: T Cells, Bone Loss, and Mammalian EvolutionSemantic proximity Read ↗

Correlating RANK ligand/RANK binding kinetics with osteoclast formation and function.Semantic proximity Read ↗

Novel RANKL DE-loop mutants antagonize RANK-mediated osteoclastogenesis.Semantic proximity Read ↗

Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.